Therapeutic Agents for the Treatment of Temporomandibular Joint Disorders: Progress and Perspective

Mengjie Wu¹, Jingyi Cai², Yeke Yu³, Sihui Hu¹, Yingnan Wang¹ and Mengrui Wu⁴*

¹The Affiliated Hospital of Stomatology, School of Stomatology, Zhejiang University School of Medicine, and Key Laboratory of Oral Biomedical Research of Zhejiang Province, Hangzhou, China, ²State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases and Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China, ³Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Department of Oral Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁴College of Life Sciences, Zhejiang University, Zhejiang, China

Temporomandibular joint disorders (TMD) are a common health condition caused by the structural or functional disorders of masticatory muscles and the temporomandibular joint (TMJ). Abnormal mandibular movement in TMD patients may cause pain, chronic inflammation, and other discomfort, which could be relieved by a variety of drugs through various delivery systems. In this study, we summarized commonly used therapeutic agents in the management of TMD as well as novel bioactive molecules in preclinical stage and clinical trials. The emerging therapy strategies such as novel intra-TMJ delivery systems and implants based on tissue engineering are also discussed. This comprehensive review will strengthen our understanding of pharmacological approaches for TMD therapy.

Keywords: temporomandibular joint, pain management, intra-TMJ injection, mandibular dysfunction, temporomandibular joint disorder

INTRODUCTION

Temporomandibular joint disorders (TMD) are complex clinical problems related to the dysfunction of the jaw joint and masticatory muscle. TMD occurs more often in women than in men aged 20–40 years old. Its estimated that the prevalence of TMD in children and adolescents varies from 6% to 68%, considering the inconsistency among diagnostic criteria and clinical examination adopted (Chang and Israel, 2005). Epidemiological studies revealed that muscle disorders, disc displacements, and other joint disorders are the most common symptoms of TMD (Osiwieciz et al., 2018).

The occurrence and progress of TMD are associated with the damage or structural alterations of the temporomandibular joint (TMJ). Pain, malocclusion, constrained and abnormal jaw motion, and joint noises are the most common chief complaints of patients with TMD. Concomitant headaches and sleep disturbances exacerbate the sharp decline of patients’ life quality. Fortunately, pharmaceutic therapies have been vastly used in the past 25 years to relieve the syndrome of TMD. The most effective pharmacological agents used to treat TMD include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, anxiolytics, muscle relaxants, antidepressants, and anticonvulsants (Ouanounou et al., 2017). We performed an electronic search of PubMed database between 2011 and July 2020 with focus on TMD, defects, and various types of novel drugs/delivery systems. Inclusion criteria were broad, and exclusion
criteria were studies that were not published in English, published before 2011, or not related to TMJ diseases or injury. Based on the included published papers, we reviewed the approved pharmacologic agents for patients with TMD, as well as novel therapy strategies in preclinical researches and clinical trials. The state-of-the-art review presents an overview of the therapy choices for treating TMD, which may strengthen our understanding of the risks and benefits of these therapeutic agents.

**TABLE 1 | Expanded taxonomy of TMD (Peck et al., 2014).**

| I. TMD | 1.A: Joint pain (arthralgia and arthritis)  
1.B: Joint disorders (disc disorders, hypomobility disorders other than disc disorders, and hypermobility disorders)  
Disc disorders: disc displacement with reduction and disc displacement with reduction with intermittent locking  
Disc displacement without reduction with limited opening  
Disc displacement without reduction without limited opening  
1.C: Joint diseases (degenerative joint disease, systemic arthropies, condylar erosions, etc.)  
1.D: Fractures  
1.E: Congenital/developmental disorders (aplasia, hypoplasia, and hyperplasia) |
|---|---|
| II. Masticatory muscle disorders | 2.A: Muscle pain (myalgia, tendonitis, myositis, and spasm)  
2.B: Contracture  
2.C: Hypertrophy  
2.D: Neoplasm  
2.E: Movement disorders (orofacial dyskinesia and oromandibular dystonia)  
2.F: Masticatory muscle pain attributed to systemic/central pain disorders (fibromyalgia/widespread pain) |
| III. Headache | Headache attributed to TMD |
| IV. Associated structures | Coronoid hyperplasia |

**Pharmacological Agents in the Clinical Management of TMD**

The etiology of TMD is complex and multifactorial, which is caused by related functional, structural, and psychological factors. TMD include muscle-related myogenic TMD and joint-related arthrogenic TMD. Touche et al. reviewed the evidence on treatment options for pain related to TMD in their Table 1. The myogenic and arthrogenic TMD is different in etiology, pathogenesis, clinical signs, and symptoms; thus, different therapeutic strategies should be employed for their pain management (Gil-Martínez et al., 2018).

Pharmacological agents are applied in TMD as a monotherapy or in combination with other approaches, such as physiotherapy, occlusal splint, and surgical intervention. Patients with chronic TMD have frequently overlapping pain conditions of systematic disease. Compared with localized TMD, they are more likely to suffer from depression and anxiety, sleep poorly, distressed and arguably. Thus, researchers and clinicians have adopted several different drug delivery routes, including oral administration, intra-articular (IA) injection, muscular injection, and topical administration, such as ointment and cream. The following sections describe the indications of each intervention and its potential therapeutic effects for TMD patients. Here, we classified commonly used TMD drugs into four groups, namely, anti-inflammatory drugs, agents with systemic nervous system actions, hyaluronic acid (HA), and glucosamine (GS), and discussed their administration methods accordingly (Figure 1).

**Anti-inflammation Drugs**

In TMD, inflammation is observed along with pain and cartilage degeneration. Therefore, drugs, such as NSAIDs and corticosteroids, which inhibit the release of inflammatory cytokines, are prescribed in TMD. The compelling analgesic and anti-inflammatory effects of NSAIDs, such as their ability to block prostaglandin synthesis by inhibiting cyclooxygenase, made this type of drugs among the first-line options for mild to moderate inflammatory pain in patients with TMD (Hersh et al., 2008). However, most NSAIDs for TMJ pain, including ibuprofen and naproxen, are given through oral administration, which might have side effects, such as the exacerbation of hypertension, gastrointestinal effects, and the worsening of renal function. The IA application of tenoxicam might be more effective than orally administered drugs in terms of anti-inflammatory and analgesic effects. Corticosteroid is another potent anti-inflammatory drug that can inhibit the release of arachidonic acid, from which prostaglandins and leukotrienes are derived. Glucocorticoids, usually diluted with local anesthetic, are most widely utilized for IA injection to patients with TMD for its potential advantages, such as its safe use, less systemic exposure, and fewer side effects (de Souza et al., 2012).

**Agents with Systemic Nervous System Actions**

Antidepressants, muscle relaxants, opioids, and anti-convulsants, which suppress the responses of the peripheral or central nervous

**CLINICAL CLASSIFICATIONS AND MANAGEMENT OF TMD**

**Research Diagnostic Criteria of TMD**

Any diagnosis of TMD comes from the evaluation of signs and symptoms. TMD has a variety of classification and nomenclature systems, including the Research Diagnostic Criteria for TMD and the American Academy of Oral and Maxillofacial Pain classification. Many modified taxonomies have been reported recently, such as a new surgical classification for TMD and a proposed classification of TMD in edentulous patients (Dimitroulis, 2013; Alzarea, 2015). Peck et al. expanded and summarized the taxonomy of TMD derived from reliable diagnostic and consensus-based diagnostic criteria (Peck et al., 2014) as shown in Table 1, which presents a state-of-the-art classification of TMD (Schiffman et al., 2014).
system (CNS), are commonly employed to relieve TMJ pain or muscular spasm. Among various antidepressants, tricyclic antidepressants and serotonin norepinephrine reuptake inhibitors seem to be the most effective for chronic pain, whereas selective serotonin reuptake inhibitors may reduce orofacial pain (Finnerup et al., 2010). Muscle relaxants are prescribed to relieve myofascial pain in TMD. Cyclobenzaprine is one of the most commonly prescribed muscle relaxants in TMD that may inhibit descending serotonergic pathways in the spinal cord by acting on 5-HT2 receptors. Most muscle relaxants function systematically in the CNS and alleviate pain by releasing the suppressive tonic flow of nerve impulses, which are later transmitted to voluntary muscles (Bal Kucuk et al., 2014). Opioid peptides, as a classical analgesia, mimic endogenous opioids and target endogenous μ-opioid receptors to inhibit the transmission and sensation of pain. Considering the uncontrollable side effects and potential abuse of opioids, their prescription is not suggested unless all other treatment options are intractable (Yip and Oettinger, 2020). Intramuscular morphine elevates mechanical pain threshold and tolerance in the masseter in TMD with little systemic effect in clinical trials (Yip and Oettinger, 2020).

Hyaluronic Acid (HA)
Along with glucocorticoids, HA is commonly administered through IA injection for TMD treatment. HA is derived from the natural component of the synovial fluid and articular cartilage; thus, it can restore the viscoelasticity of the synovial fluid in an inflamed joint and has lubrication, shock absorption, and joint protection effects (Evans et al., 2014). Moreover, HA can interact with different receptors to exert effects in anti-inflammation, cartilage synthesis, and chondroprotection (Webb and Naidoo, 2018). The pain alleviating effects of HA and glucocorticoid seem nearly the same, although the repeated IA injection of glucocorticoids may lead to degenerative changes in the joint, which is not seen during the use of HA (Heir, 2018). Moreover, intramuscular injection of collagen has also been shown to be an efficient method for reducing myofascial pain within masseter muscles (Nitecka-Buchta et al., 2019a).

Glucosamine (GS)
GS is the metabolic precursor for extracellular matrix synthesis and has been reported to inhibit cartilage decomposition and promote proteoglycan synthesis (Wu et al., 2013). As an over-the-counter medicine, GS appears to be safe, and oral GS is usually prescribed as an adjunct to HA injection in treating TMJ osteoarthritis. These traditional therapies are mostly empirical treatment without potent evidence to support their effectiveness and coherence.

NOVEL MOLECULAR AGENTS FOR TMD TREATMENT

Traditional pharmacological agents for TMD are effective but have unavoidable side effects and unwanted interaction with commonly used drugs. Thus, novel and safer therapeutic
strategies are still in great demand. In the past decades, great progress has been achieved to discover new chemical entities for the prevention and treatment of various TMD syndromes. Among these prophylaxis, plant-derived compounds and crude extracts stand out, and other medical products, such as ozone and platelet-rich plasma (PRP), were also tested in clinical study (Daif, 2012; Rahimi-Movaghar and Eslami, 2012; Celakil et al., 2019). Drug repurposing strategy was as well employed in clinical trials to evaluate the efficacy of FDA-approved anti-arthritis drugs, such as celecoxib, for TMD therapy or the new combinations of existing TMD drugs. In this part, we summarized the treatments used in preclinical research and clinical trials as shown in Figure 2.

Bioactive Compounds in Preclinical Studies
Naturally occurring products have long been reliable and abundant resources for drug development (Li and Vederas, 2009). Nature derivatives with anti-inflammatory and analgesic effects hold great promise for application in TMD medication. Lectins, extracts from plants and algae, sulfated polysaccharides (SPs), and isolated compounds, such as terpene, are among the widely explored nature-derived agents, and a latest review with relatively strict inclusion criteria provided a hint to this field but without elucidating their mechanisms. Our understanding of the side effects and proper dosage of these natural products are lacking; thus, preclinical research on these drugs should be highlighted. TMD rat models provide a good platform to test these drugs. In a rat disease model, TMD could be stimulated through the IA injection of various agents, such as formalin, capsaicin, serotonin, carrageenan, and mustard oil. Formalin, as an agonist of transient receptor potential ankyrin subtype 1 protein (TRPA1), which is a nonselective cation channel expressed in pain-sensing neurons and a promiscuous chemical sensor involved in sensory hyperreactivity in visceral organs, has been used to establish a stable model for an orofacial nociception study (Coura et al., 2017; Melo et al., 2017). Capsaicin, as a derivative from red pepper, binds to transient receptor potential cation channel subfamily V member 1 (TRPV1) to activate sensory terminals and stimulate burning pain after injection (Ribeiro et al., 2020). The nociception induced by serotonin is realized in a rather indirect way on primary neurons via the activation of sympathomimetic amines and the synthesis of prostaglandin (Ribeiro et al., 2020; Oliveira-Fusaro et al., 2012). Zymosan, a polysaccharide derived from yeast cell walls, could induce severe and erosive arthritis and severe pain once injected (do Val et al., 2014). Carrageenan and mustard oil could induce plasma protein extravasation and leukocyte migration; mustard oil simultaneously causes in neuron depolarization and neurogenic inflammation, whereas carrageenan represents the non-neurogenic one (Clemente-Napimoga et al., 2019). The vibrissal pad injection of complete Freund’s adjuvant (CFA) has also been developed as a reliable model for TMD study (Luo et al., 2020). Researchers observe the duration of nociceptive behaviors, such as scratching orofacial regions, reflex response, or mechanical allodynia, to assess the severity of pain and measure TMD relief. Samples, including synovial fluid and periarticular tissues, are also obtained to test for inflammatory factors, granulocyte infiltration, and vascular permeability. However, although these novel therapeutic agents might open avenues to treat TMD, their efficacy and probable toxicity profiles are still waiting to be exploited in the future for better and safer application.
Lectins
Lectins are a heterogeneous group of proteins that possess noncatalytic domain binding sites and exhibit specific and reversible binding ability to simple sugars or complex carbohydrates. Considering the wide distribution and reliable medical effects of lectins as anti-inflammation factors, several plants have been tested for lectin extraction and TMD treatment. First, lectin from Dioscea violacea (DVL) was verified to have high affinity with ligands, such as α-methyl-D-mannoside, N-acetyl-D-glucosamine, and core I sialyl Lewis X (core 1-sLeX). In TMD rat models induced by either carrageenan or mustard oil as non-neurogenic and neurogenic types, respectively, the application of DVL impaired the inflammation process and may serve as a promising strategy for TMD treatment (Clemente-Napimoga et al., 2019). Mechanically, leukocytes bind to endothelial cells to enable their extravasation and then transfer to the inflammation spot, in which the appropriate interaction between selectins and their ligands is needed (Noursrargh and Alon, 2014). DVL, as a selectin, could bind and block the core 1-sLeX on the surface of leukocytes, inhibit the ligand-selectin bound to endothelial cells, decrease intercellular adhesion molecule-1 expression, and thus inhibit leukocytes from rolling and binding to the surface of endothelial cells and the subsequent inflammatory process. Lectin from Abelmoschus esculentus exert antinociceptive and anti-inflammatory effects on zymosan-induced TMJ pain partially by inhibiting inflammatory cytokines, such as TNF-α and IL-1β, and by depending on the integrity of heme oxygenase 1 (HO-1), whose reduction would facilitate the inflammation process (Freitas et al., 2016). Meanwhile, the activation of central δ and κ opioid receptors serve as another explanation of its antinociceptive effect (Alves et al., 2018). Notably, lectin from Caulerpa cupressoides has a role in TMJ related to TNF-α and IL-1β inhibition but is independent of the HO-1 pathway or opioid receptors (da Conceição Rivanor et al., 2014). Lectin isolated from the seeds of Artocarpus incisa L., such as frutalin, acts as an inhibitor of orofacial nociception in acute and chronic pain, which is mediated by TRPA1, TRPV1, and transient receptor potential melastatin 8 receptors (Damasceno et al., 2016). As information mediators, lectins play an essential role in inflammation and pain; thus, their importance is worthy of further exploration.

Moringa oleifera Lam
M. oleifera L. is a folk recipe in the tropics utilized for diversified medical purposes, including anti-inflammation. Although M. oleifera has considerable therapeutic effects, its wide application is retarded because their properties lack elucidation. Researchers have developed a set of derivations of extractions from M. oleifera and tested the toxicological index of each molecule, which confirmed that MC-D7, MC-D9, and MC-H1 are safe analogs. Furthermore, hypernociception is reduced comparatively by the application of these three molecules in a rat model of TMD, which may be explained by their mediation on the inflammatory factors, along with the effect on the NF-κB signaling pathway by suppressing the degradation of IκB. Reduction of the vascular permeability was also observed in this study (Dos Santos et al., 2018). Another in vitro program proved that moringin is a potent agonist of the TRPA1 channel (Borgonovo et al., 2020). Thus, the application of these analogs would benefit TMD treatment in a relatively safe way with few side effects.

Tephrosia toxicaria Pers
T. toxicaria P. is also perceived as a folk recipe in Amazonian countries for pain and inflammation alleviation. T. toxicaria P. relieves inflammatory hypernociception in the TMJs of rats hypothetically depending upon the integrity of the HO-1 pathway (do Val et al., 2014). Another study in mice provided evidence that its anti-inflammatory activity is related to the inhibition of pro-inflammatory cytokines, such as TNF-α and IL-1β, as well as the NO-dependent inhibition of leukocyte recruitment (Martinez et al., 2013).

Euphorbia bicolor Latex Extract
Patients with TMD have remarkably elevated oxidative stress biomarkers and reduced total antioxidant capacity, which suggest the potential effects of novel therapeutics with antioxidant and free radical scavenging activities (de Almeida and Amenábar, 2016). Recently, corresponding analgesia was observed with the injection of E. bicolor latex extract in a rat model of orofacial pain. In this process, its role in antioxidant activities matters. Basically, the extract downregulated the level of advanced oxidation protein product (AOPP), leading to fewer reactive oxygen species (ROS) produced via Nox4, which would be followed by a consequential decrease in activation of TRPV1 as the peripheral pain generator (Busu et al., 2019). The molecule provided a cure for both acute and chronic pain and functioned independently of the opioid receptors, which indicate its medical potential (Busu et al., 2019).

SPs from Marine Algae–derived Products
Apart from terrestrial resources, marine algae–derived products also represent a set of promising agents, among which the abundant repertory of SPs stands out in the pharmaceutical industries for TMD treatment. Here, we listed three SPs available for TMD management, namely, the purified SPs from Caulerpa racemosa (Cr), the polysaccharide fraction I of Gracilaria cornea (Gc-FI), and SPs (Fraction F II) from red seaweed Solieria filiformis. SPs from Cr and Gc-FI share common effects on inflammation-related cytokines, that is, Cr reduces TNF-α and IL-1β, whereas Gc would do the same downregulation and increase the release of IL-10 (Coura et al., 2015). However, discrepancies were also observed. First, pretreatment with Cr alleviates the TMD induced by serotonin, but the same application of Gc-FI failed to provide an improvement. This finding suggests that the inhibition of sympathomimetic amines and prostaglandin synthesis, which are found in Cr but not in Gc-FI, are required for the treatment to work. Second, hypernociception in animal models requires different neurotransmitters and neuromodulators, such as nitric oxide (NO) and carbon monoxide (CO), which represent the NO/cyclic guanosine monophosphate/protein kinase G/ATP-sensitive potassium channel (NO/cGMP/PKG/K+ATP) pathway and the heme oxygenases (HO)/CO/cGMP/PKG pathway, respectively, to regulate nociception. Gc-FI is dependent on NO and CO, whereas Cr only relies on the HO-1 pathway and its
functionality not influenced by the integrity of NO (Ribeiro et al., 2020; Coura et al., 2017). Last, Gc-FI also depends on the activation of opioid receptors to exert its antinociceptive effect, which was also confirmed in SPs from S. filiformis (Arã­jo et al., 2017). Rather than being selective, SPs from S. filiformis interact with all the three opioid receptors in the TMJ hypernociception of rats, such as morphine, and thus may serve as a relatively safer alternative for opioids.

**Terpene**

Terpene is a large category of structurally diverse molecules and includes primary and secondary metabolites. As the main constituent of essential oils, the demand for terpene in the cosmetic and pharmaceutical industries keeps on increasing for years (Melo et al., 2017; Paramasivan and Mutturi, 2017). (−)-α-bisabolol (BISA), a sesquiterpene widely used commercially as a cosmetic ingredient, gained the classification as “generally regarded as safe” from the FDA. Several studies have confirmed its efficacy in TMD pain as an antagonist to TRPA1 and are associated to TNF-α but not IL-1β reduction (Barreto et al., 2016). BISA also appears to be effective against trigeminal neuropathic pain for its role in central sensitization after the transection of the infraorbital nerve (Melo et al., 2019). Notably, the efficacy of the oral or topical administration of BISA suggests its clinical importance as a promising adjuvant for orofacial pain treatment. Interestingly, a clinical research already verified that BISA mouthwash contributes to pain relief and healing in postoperative maxillofacial surgeries (Amora-Silva et al., 2019). Similarly, eucalyptol, a natural monoterpenoid used as the main active component of several essential oils, including that extracted from Tasmanian bluegum, has antinociceptive effects via its antagonism to TRPA1 (Melo Júnior et al., 2017). More research into the therapeutic roles of terpenes would be of antagonism to TRPA1 (Melo Júnior et al., 2017). More acids (SCFAs) in the gut and relevant bacteria, such as Bacteroidetes and Lachnospiraceae, decreased, and by reversing this CFA-caused reduction and restoring the normal gut microbiota, RSV can resist the inflammatory process and maintain the integrity of the blood–brain barrier (BBB), block the activation of microglia, and inhibit the release of TNF-α in the spinal trigeminal nucleus caudalis (Sp5C) (Ma et al., 2020). This interaction between gut bacteriome and TMD deserves attention, and the trial of RSV should be an interesting starter.

Natural bioactives have provided relief to millions before the development of modern medicine and represent a precious and enormous repertory for drug exploration. Studies aiming to elucidate the characteristics of these products bear significance for pharmacology and show their effect on curing TMD. Unfortunately, in most studies mentioned above, the therapeutic effects were tested in acute models of inflammation in TMJ, whereas the TMD was presented with a chronic progress. **Table 2** summarizes the progress of natural-derived bioactives and their potential pharmacological effects. For further application, chronic models should be established and utilized to explore their potential relief to TMD. Meanwhile, the dosage and toxicology should be further elucidated. Strategically, given their sharing of target with the HO-1 pathway, cytokine factors, and TRPA1 and TRPV1 receptors, the efficacy among novel molecules and with traditional remedies should also be displayed. From another point of view, novel drugs as dietary therapy such as cocoa, topical application of BISA, and RSV targeting gut microbiome suggest that combinational remedy should be considered with these molecules as potent supplements.
### TABLE 2 | Summary of novel treatments for TMD.

| Ref and trails | Novel molecule | Intervention | Efficacy | Mechanism |
|----------------|----------------|--------------|----------|-----------|
| Clemente-Napimoga et al. (2019) | Dioclea violacea lectin | Intravenously injection | Carrageenan/mustard oil induced: anti-inflammatory; Zymosan-induced: antinociceptive and anti-inflammatory; Formalin-induced: central antinociceptive | 1) Suppressing ICAM-1; 2) Blocking the ligands on leukocyte receptor |
| Alves et al. (2018) | Abelmoschus esculentus lectin | Intravenously injection | Zymosan-induced: antinociceptive and anti-inflammatory; Formalin-induced: central antinociceptive | 2) Inhibiting TNF-α and IL-1β; 3) Activation of α and κ opioid receptors but not of μ opioid receptors |
| da Conceição Rivanor et al. (2014) | Caulerpa cupressoides lectin | Intravenous injection | Zymosan-induced: antinociceptive and anti-inflammatory; Formalin/glutamate/capsaicin induced: antinociceptive | 1) Depending on HO-1 pathway; 2) Inhibiting TNF-α and IL-1β; 3) Activation of δ and κ opioid receptors but not of μ opioid receptors |
| Damasceno et al. (2016) | Lectin of seeds of Artocarpus incisa L./Frutalin | Intraperitoneally injection | Formalin/glutamate/capsaicin induced: antinociceptive | Modulating TRPA1, TRPV1, and TRPM8 receptors |
| Dos Santos et al. (2018), Borgono et al. (2020) | Moringa oleifera Lam | Per os | Formalin-induced: antinociceptive and anti-inflammatory (MC-D7, MC-D9, and MC-H); Serotonin-induced: antinociceptive (only MC-H) | 1) Mediation on the inflammatory factors; 2) Agonist of TRPA1 |
| Coura et al. (2017) | Gracilaria cornea | Subcutaneous injection | Formalin-induced: antinociceptive; Serotonin (5-HT)-induced: No effect | 1) Activating opioid receptor; 2) Depending on NO/cGMP/PKG/K+ATP pathway and the HO/CO/cGMP/PKG pathway; 3) Inhibiting TNF-α and IL-1β and increasing IL-10 |
| Ribeiro et al. (2020) | Caulerpa racemosa | Intravenous injection | Formalin/capsaicin/serotonin-induced: antinociceptive and anti-inflammatory | 1) Depending on HO-1 pathway; 2) Inhibiting TNF-α and IL-1β |
| Araújo et al. (2017) | Solenia filiformis | Subcutaneous injection | Formalin/serotonin-induced: antinociceptive and anti-inflammatory | 1) Activating 3 opioid receptors in the subnucleus caudalis; 2) Inhibiting the release of inflammatory mediators in the periarticular tissue |
| do Val et al. (2014); Martinez et al. (2013) | Tephrosia toxicaria Pers | Injection | Zymosan-induced: antinociceptive and anti-inflammatory | 1) Depending on HO-1 pathway; 2) Inhibiting TNF-α and IL-1β; 3) NO-dependent inhibition of leukocyte recruitment |
| Basu et al. (2019); Barreto et al. (2016); Amora-Silva et al. (2019); Melo et al. (2019) | Euphorbia bicolor (Euphorbiaceae) latex | Injection into the inflamed vibrissal pad. | CFA-induced: antinociceptive and anti-inflammation | 1) Down-regulating AOPP, ROS, Nox4, iNOS; 2) Inactivating TRPV1 |
| Basu et al. (2019); Barreto et al. (2016); Amora-Silva et al. (2019); Melo et al. (2019) | (-)−α-bisabolol (BISA) | Oral administration | Formalin-induced: antinociceptive and anti-inflammatory | 1) Antagonist of TRPA1; 2) Inhibiting TNF-α but not IL-1β |
| Melo Júnior et al. (2017) | Eucalyptol | Oral administration | Formalin/mustard oil-induced: antinociceptive | Antagonist of TRPA1 |
| Cady and Durham (2010) | Cocoa | Cocoa-enhanced diet for two weeks | Capsaicin/CFA-induced: antinociceptive and anti-inflammatory | 1) Elevating the basal level of MKP-1 and MKP-3 in neurons; 2) Inhibiting CGRP; 3) Decreasing iNOS |
| Cady et al. (2010) | Grape seed extract | Grape seed extract-enhanced diet for 2 weeks | CFA-induced: antinociceptive | 1) Elevating the basal level of MKP-1 in trigeminal nerve; 2) Elevating the basal level of GLAST and decreasing that of CGRP in spinal; 3) Suppressing expressions of P-p38, OX42, and GFAP under CFA-induced pain |
| Magni et al. (2018) | Purple corn extract | Drink purple corn extract for 2 weeks | CFA-induced: antinociceptive | 1) Reducing trigeminal macrophage infiltration; 2) Shift of microglia cell polarization to a neuroprotective phenotype |

(Continued on following page)
TABLE 2 (Continued) Summary of novel treatments for TMD.

| Ref and trails | Novel molecule | Intervention | Efficacy | Mechanism |
|----------------|----------------|--------------|----------|-----------|
| Ma et al. (2020) | Resveratrol | Intraperitoneally injection for 4 days | CFA-induced: anti-inflammation | 1) Reversing CFA-caused reduction of SCFAs and recovering CFA-decreased Bacteroidetes and Lachnospiraceae in the gut 2) Rescuing CFA-caused BBB leakage 3) Blocking CFA-enhanced microglial activation and expression of TNF-α in the Sp5C |
| Dehghan (2015) NCT02794922 | Vitamin B complex | Oral administration | Stronger analgesic property than vitamin E and diclofenac | 1) Protecting cell membrane against peroxidation 2) Enhancing norepinephrine and 5-ht 3) Interacting with opioids receptors 4) Regulating the release of NO |
| Light et al. (2009); Tchivileva et al. (2010) NCT02437383 | Propranolol | Oral administration | Suppress alveolar bone loss and osteoclast hyperactivities | Blockage of β-ARs signal pathway |
| Ivković et al. (2018) | Estrogen | Oral administration | Reduce hormonal fluctuation related TMD pain | Inhibiting effects caused by abrupt hormonal changes as following: 1) Fibrocartilage degenerative changes 2) Psychophysical symptoms 3) Abnormal Telper 1 and Telper 2 -mediated response |
| Kolok et al. (2017); Zeng et al. (2016) NCT03675659 | Magnesium sulfate | Intra-articular injection | Pain relieving | 1) Blocking NMAD-dependent nerve system activities 2) Suppressing calcium entrance 3) Regulating SOX9 expression 4) Immune modulatory effects |
| Zotti et al. (2019) NCT03655275 | Platelet-rich plasma | Intra-articular injection; Combined with arthrocentesis | Better performance than arthrocentesis alone or combined with HA | 1) Promotes cell proliferation and inhibits nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation 2) Promote cartilage matrix production 3) Increasing HA concentration 4) Stabilizing angiogenesis 5) Anti-inflammatory and regenerative effects |
| Rahimi-Movaghar and Eslami (2012); Daif (2012); Celakil et al. (2019) NCT02997410 | Ozone | Ozonized oil/gas injection Noninvasive form | Pain relieving | 1) Boosting joint-repairing abilities of fibroblasts 2) Anti-inflammation 3) Chondrogenesis |
| Christidis et al. (2014); Christidis et al. (2015) NCT022330371 | Granisetron | Intramuscular tender-point injections | Pain relieving | 5HT-3 selective serotonin receptor antagonist |
| Thambar et al. (2020) | Botulinum toxin | Intramuscular injections | Controversial | 1) Reducing parafunctional motions 2) Analgesic effect for antagonizing the release of substance P, glutamate, and calcitonin gene regulated peptide |
| Toth et al. (2010); Giacoppo et al. (2015) NCT03994640 | Cannabidiol | Transdermal delivery | Pain relieving | 1) Acting on the CB2 receptors 2) Binding TRPV1, GPR55 and 5-HT-1A 3) Lowering oxidative and nitrosative stress |

Agents in Clinical trials for TMD Therapy

Clinical trials are essential to verify the toxicity and efficacy of pharmacological agents of TMD. Thus far, nearly a dozen TMD-related clinical trials have been updated in clinicaltrials.gov(https://clinicaltrials.gov/). Most studies were in phase II, and the number of participants ranged from dozens to hundreds. In general, several symptoms, including the range of mandibular motion, tenderness of muscle of mastication, and the severity of pain, were tested to evaluate the efficacy of relief, along with the analysis of synovial fluid. Desirable outcomes of clinical trials will provide potent evidence for the extensive use, whereas the detailed mechanism of these drugs should be explored to achieve medication in a precise and accurate manner.

Orally Administrated Agents

Vitamin B Complex

An intramuscular injection of diclofenac + B vitamin mixture showed a superior analgesic effect compared with the injection of diclofenac alone (Magaña-Villa et al., 2013). A human experiment of patients with knee OA indicated stronger analgesic property of vitamin B than vitamin E and diclofenac; the study highlighted the potential effects of vitamin B on TMD (Dehghan, 2015). Mechanically, the anti-inflammatory and
analgesic effect may relate to the cyclooxygenase pathway and opioid receptors (Tamaddonfard et al., 2018). Notably, the analgesic effects of B vitamins are not equivalent, with vitamin B12 being more therapeutically beneficial to pain management (Buesing et al., 2019).

**Propranolol**
Propranolol is a racemic mixture in which the S(-)-enantiomer dominates the binding affinity for β-adrenergic receptors (β-ARs). This compound is officially approved for the treatment of conditions, such as cardiac conditions, tremor, migraine, and pheochromocytoma. Emerging clinical evidence indicated that propranolol provides efficacious treatment for the pain management of TMD via the blockage of β-AR signal (Light et al., 2009; Tchivileva et al., 2010). In osteoarthritic joints, evidence of hyperactivities of subchondral bone remodeling and sympathetic nerve fiber sprouting in the osteochondral junction has been displayed (Pongratz and Straub, 2013; Suri and Walsh, 2012). The TMD patients also showed an impaired activation of the sympathetic–adrenergic component of the autonomic nervous system under stress. The elimination of abnormal sympathetic signals by blocking β-ARs will suppress alveolar bone loss and osteoclast hyperactivities (Jiao et al., 2015).

**Estrogen**
TMD prevalence is unequal between genders, with the estimated male to female ratio of patients suffering from TMD at around 1:3 (Manfredini et al., 2011). Meanwhile, for several female patients suffering from TMD, their menstrual cycles influence the severity of pain systematically as the highest pain occurs during menses and late luteal phase (LeResche et al., 2003). The predisposition and fluctuation of pain can be related to female reproductive hormones, especially estrogen. The effect of estrogen on TMD pain processing is multifaceted. First, estrogen retards fibrocartilage degenerative changes (Robinson et al., 2018). Meanwhile, abrupt hormonal changes can simultaneously cause psychophysical symptoms, possibly exacerbating the pain caused by TMD (Smith et al., 2006). Moreover, the perplexed role of estrogen may relate to their immune and nervous system effects. Reduced and elevated estrogens separately promote T helper 1 (Th-1) and Th-2-mediated response to realized their pro- and anti-inflammatory effects (Ivkovic et al., 2018). The appropriate estrogen regulation across the hormonal cycle works for TMD pain. However, a systematic review evaluating the estrogen effect on TMD in humans revealed that the relationship can be divergent and occasionally contradictory (Berger et al., 2015). A recent review suggested that sex and age-specific estrogen signaling matters when evaluating the effect of estrogen in TMD, and more specific drugs should be developed (Robinson et al., 2020). Thus, studies with larger enrollment of participants can verify the potential of estrogen for general prescription.

**Agents for IA Injection or Intramuscular Injection**

**Magnesium Sulfate**
Magnesium sulfate is a small colorless crystal usually used as an anticonvulsant. Additionally, as an antagonist of N-methyl-D-aspartate (NMDA) receptor, magnesium can modulate pain perception by blocking the nerve system activities that depend on NMDA and achieve the chondrocyte protective effects via decreasing the superfluous entry of extracellular calcium into cells (Srebro et al., 2017). Magnesium sulfate exerts systemic and local immune modulatory effects, potentially relieving the inflammatory pain. For clinical use, IA magnesium sulfate in the knee is suggested as a potential analgesic agent with a low chondrotoxicity and limited side effects. Furthermore, the analgesia effect in patients undergoing surgery with spinal anesthesia has been confirmed (Shah and Dhengle, 2016). Given these information, further exploration of magnesium sulfate in TMD will be worthwhile.

**Platelet-rich Plasma (PRP)**
Consequent pain and motor disturbance in TMD relates to the increased pressure in the joint and to the high amount of cytokines in the synovial liquid (Fernández-Ferro et al., 2017). Sole arthrocentesis of TMJ has achieved satisfying results. Still, researchers continually exploit optimal materials to inject or perform arthrocentesis with PRP, produced by centrifuging heparinized whole autologous blood and separating the platelets from the other blood components, gained extensive attention given that concentrated platelets contain multiple growth factors (GFs). Impressively, PRP not only promotes cell proliferation and cartilage matrix production while inhibiting nuclear factor-κB ligand–induced osteoclast differentiation but also increases the HA and regulate angiogenesis (Hegab et al., 2015; Wang et al., 2018). A latest review based on 10 qualified studies that assessed the effectiveness of PRP use in TMD confirmed that the outcomes of PRP, either by injection or combined with arthrocentesis, exceed that of arthrocentesis alone or combined with HA. Alternatively, the latest generation of PRP, that is, liquid-phase concentrated GF (LPCGF), requires no anticoagulants nor the addition of other agents and possesses a stronger effect than PRP. Researchers indicated that 2 ml LPCGF is highly stable and effective when used to assuage TMD (Yang et al., 2017). PRP prolotherapy is tempting for TMD treatment, given its advantage in regeneration.

**Ozone**
For medical purposes, the potent oxidant, ozone gas, is administered in various forms, such as ozonized oil, besides in gaseous state (Suh et al., 2019). When administered in a joint capsule as a highly reactive molecule, it can boost the joint-repairing abilities of fibroblasts and exert effects, including anti-inflammation and chondrogenesis properties. IA ozone gas injection to treat internal derangement of the TMJ has received recognition. Recently, a noninvasive treatment with improved user experience and positive outcomes was put into use in a device that relies on a glass omega probe to conduct the high-frequency bio-oxidative ozone generated by voltage power.

**Granisetron**
In conditions such as tissue damage or ischemia, the neurotransmitter serotonin 5-HT is released from platelets and mast cells and mediates myalgia and hyperalgesia subsequently by activating the 5-HT-3-receptor. The finding showing the elevated
expression of 5-HT-3A-receptor in muscle nerve fibers in women with TMD provides a new therapeutic target (Christidis et al., 2014). Granisetron, a 5HT-3 selective serotonin receptor antagonist, is generally used as an antiemetic and anti-nauseant for cancer chemotherapy patients. Notably, its efficacy as an analgesic was confirmed after repeated intramuscular tender-point injections to patients with chronic TMD (Christidis et al., 2015).

**Botulinum Toxin (BTX)**
BTX is a 150 kDa exotoxin produced by *Clostridium botulinum*, with serotype A (BTX-A) being the most readily available. Once taken by the synapse via receptor-mediated endocytosis, it can cleave synaptosomal-associated protein 25 (SNAP-25) and consequently hamper acetylcholine release from pre-junctional nerves. The inhibition effect on exocytotic activity at the neuromuscular junction would ultimately lead to muscle weakness. Meanwhile, BTX could as well modulate sensory processing for it partially antagonizes the release of substance P, glutamate, and calcitonin gene-regulated peptide (Malgorzata et al., 2017). As for TMD treatment, the capability to reduce parafunctional motions involving the masticatory muscles and algogenic effects may account for BTX's efficacy. Nevertheless, a latest review provided no clear consensus on the clinical outcomes in the last 30 years. Thus, more tests with high reliability on the therapeutic benefit of BTX for myofascial TMD should be conducted in the future (Thambar et al., 2020).

**Other Noninvasive Delivered Agents**
A wide range of indications, of which pain relief is the most attractive, show that *Cannabis sativa* (CB)-related drugs may hold promise. However, a high potential for abuse and controversial psychoactive properties, presumably mediated by cannabinoid receptors (CB1 and CB2) expressed in the CNS, contributes to its limited applications. For clinical use, researchers performed multiple attempts to achieve the desirable hyperalgesia and algodynia effect while minimizing the side effects. On one side, peripherally restricted CB1 receptor agonists are a plausible solution. No penetration through the BBB of the agents is likely to circumvent their psychoactive component and has anti-inflammatory and antioxidant properties independent of Δ9-tetrahydrocannabinol (Δ9-THC) (Xu et al., 2020). Evidence shows that CBD can act on the CB2 receptors to inhibit the inflammatory state (Toth et al., 2010), whereas a portion of its effects is realized by binding TRPV1, G protein-coupled receptor 55, and 5-HT-1A other than the CB mechanism. A low level of oxidative and nitrosative stress was also observed due to CBD application (Giacoppo et al., 2015). Clinical trials applying CBD compounded by transdermal delivery in the treatment of painful peripheral neuropathy, and TMD provided positive evidence showing CBD as a promising agent against neuroinflammation and neurodegeneration (Giacoppo et al., 2015). Application of CBD formulation over masseter muscle is also reducing myofascial pain in patients (Nitecka-Buchta et al., 2019b). Furthermore, transdermal delivery may be an effective alternative considering the management of this particular drug.

In the exploration of novel molecules for TMD treatment, researchers exerted efforts in identifying and testing ideal candidates, and several desirable results have been obtained. Typically, traditional or developed drugs that possess anti-inflammation and/or antihypernociception properties dominate the lists of promising candidates. Factors, including inflammatory cytokines, opioid receptors, CO/NO transmitters, and ROS production, are the hotspot of mechanism exploration, which echoes the functions of traditionally used TMD drugs but with less side effects. On the other hand, new targets, including hormone fluctuation, abnormal muscle activities, and psychological factors, provide hints for the use of novel drugs, such as estrogen. Thus, with the additional knowledge on TMD, more promising aspects and targets for drugs and the combination of drugs favoring different mechanisms will probably serve as new and economic medication strategies. From another aspect, the degree of cooperation of patients, which occasionally overrides the efficacy of other drugs, should also be considered when developing new drugs. Novel molecules, such as vitamin B, ozone, BTA, and CBD, can provide better medication experience to patients, considering the “nutrient property” of vitamin B, the long interval of BTA injection, and the noninvasive properties of ozone and CBD application. These drugs can be used to convince patients to accept and stick to the therapy, which will greatly improve the efficacy when the drug itself performs similarly to others. In conclusion, novel molecules developed these years for TMD have been illustrated, and they may serve as a hint for researches to explore further future applications.

**NOVEL INTRA-ARTICULAR BIOACTIVE AGENT DELIVERY SYSTEMS FOR TREATING TMD**
As demonstrated above, multiple therapeutic molecules are effective for TMD treatment through noninvasive approaches (i.e. oral analgesics, antidepressants, and NDAIDs) or minimally invasive ones (i.e. intra-TMJ injection of NSAIDs, corticosteroid, HA, and arthrocentesis). However, systematic side effects from oral drugs, such as gastrointestinal damage, cardiovascular risk, and anaphylaxis, and those from frequent intra-TMJ injections, including dizziness, dry mouth, and possible drug addiction, are raising concern. Meanwhile, conventional palliative drug treatments show limitation in the regeneration of chronic and severe TMD (Dashnyam et al., 2018; Donahue et al., 2019). Therefore, novel IA systems, several of which show potential in animal TMD model, that contain biomaterials, cells, and/or bioactive molecules for sustained drug release and TMJ tissue regeneration are attracting attention (Table 3).

**Novel Delivery Systems for Therapeutic Agents**
Rapid clearance of intra-TMJ injected drugs, such as HA and corticosteroids, requires frequent injections, thus resulting in
complications, including infection, fibrous repair, and further joint damage (Dashnyam et al., 2018). Hydrogels and micro- and nanoparticles can assist in sustained therapeutic agent release to address these disadvantages (Figure 3).

Thermosensitive hydrogels exhibit liquid-to-solid transition capability that is tunable to acquire IA gelation. Chitosan is a biocompatible and biodegradable natural material, whereas β-glycerophosphate (β-GP) is an FDA-approved organic compound. Talaat et al. developed chitosan hydrogels with various β-GP concentrations with in vivo gelation time of several minutes. With the incorporation of HA, the hydrogel constantly released the drug in rabbit TMJ for 7 days (Talaat et al., 2016).

| TABLE 3 | Novel intra-articular delivery system in animal TMD models. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Delivery type** | **Material type** | **Material** | **Cell** | **Molecule** | **Test model** | **Outcome** | **Reference** | **Year** |
| **Delivery system for therapeutic agents** | Hydrogel | Natural | Chitosan+β-GP | - | HA | Rabbit TMJ | Thermosensitive hydrogel releasing HA for over 7 days | Talaat et al. (2016) | 2016 |
| | Microparticle | Natural | Gelatin | - | Ibuprofen | Rat TMJ | Microcapsules biocompatible and reduce TMJ OA pain | Kramer et al. (2012) | 2012 |
| | Synthetic | PLGA | - | siRNA-PEI | Rat TMJ | Reduced inflammatory expression and nociceptive reaction for 7 days | Mountziaris et al. (2012) | 2012 |
| | Nanoparticle | Synthetic | PLGA | - | 15 days-POJ2 | Rat TMJ | Decreased IL-1β release and nociceptive behavioral response | Clemente-Napimoga et al. (2012) | 2012 |
| | Synthetic | CP + CCT + Pluronic F68 | - | Naproxen | Rat TMJ | Reduced IL-1β and TNF-α for over 7 days | Guiterme et al. (2019) | 2019 |
| | Synthetic | MSN-CC-PEI | - | HAS2 | Rat TMJ | Promoted endogenous HA production and reduced synovial inflammation for 3 weeks | Li et al. (2019) | 2019 |
| **Delivery system for regenerative agents** | Hydrogel | Synthetic | Pluronic F-127 | Chondrocyte | - | Goat condyle defect | Neocondylar surface covered with fibrocartilaginous tissue | Yu et al. (2011) | 2011 |
| | Synthetic | Pluronic F-127 | Chondrocyte | - | Goat condyle defect | Goat condyle defect | The co-culture system provides chondrogenic environment for BMSC chondrogenic differentiation | Sun et al. (2018) | 2018 |
| | Scaffold | Natural | Collagen | Whole BM | - | Rabbit disc defect | Defect healed with new connective tissue in 2 weeks | Kobayashi et al. (2015) | 2015 |
| | Natural | Collagen | - | - | Rabbit disc defect | Disc regenerated with normal collagen expression in 3 months | Wang et al. (2017) | 2017 |
| | Synthetic | PLGA | BMSC | - | Goat condyle defect | Goat condyle defect | Osteochondral recover within 24 weeks | Zhu et al. (2011) | 2011 |
| | Synthetic | PLGA | - | TGF-β1+BMP-2 | Rabbit condyle defect | Rabbit condyle defect | Osteochondral repair after 6 weeks | Dormer et al. (2011) | 2011 |
| | Synthetic | PLA | ASC | TGF-β1 | Rabbit disc defects | Multiphase fibrocartilaginous recovery after 4 weeks | Ahtiainen et al. (2013) | 2013 |
| | Synthetic | PCL + PLGA | - | CTGF + TGF-β3 | Rabbit disc defects | Multiphase fibrocartilaginous recovery after 4 weeks | Tarafder et al. (2016) | 2016 |
| | Assembled cells | Natural | Chondrocyte | - | Minipig disc thinning | Integration with host tissue within 8 weeks | Vapniarsky et al. (2018) | 2018 |
Microparticles, with their spherical shapes sized tens to hundreds of micrometers, are suitable to carry agents that interact extracellularly with the host tissue and avoid clearance by phagocytosis (Dashnyam et al., 2018). By contrast, nanoparticles, which are of tens to hundreds of nanometers, possess large surface-to-mass ratio and enter target cells to regulate their fate (Seo et al., 2017).

The natural material gelatin was adopted as a microcapsule to deliver ibuprofen, which showed biocompatibility in rat TMJ and relieved pain from OA (Kramer et al., 2012). In addition, biodegradable synthetic poly (lactic-co-glycolic acid) (PLGA) can be processed into micro- or nanoparticles. For example, PLGA microcapsules loaded with 15 days-PGJ2 decreased IL-1β release and nociceptive behavioral response in rat TMJ (Clemente-Napimoga et al., 2012). Intriguingly, from PLGA microparticles built by Mountziaris et al., the anti-FcγRIII siRNA and the transfecting agent poly (ethylenimine) (PEI) was delivered distinctly, and they were then immediately assembled into nanoscale polyplexes. The system displayed 28 days of controlled release ex vivo and alleviation of inflammation and nociceptive reactions in rat for one week (Mountziaris et al., 2012; Mountziaris et al., 2010). In addition, Guilhaume and colleagues established a nanostructured lipid carrier with the mixture of cetyl palmitate and capric/caprylic triglycerides and the cooperation of Pluronic F68. The deliverer contributed to the administration of naproxen, reducing the IL-1β and TNF-α levels in rat TMJ for over 7 days (Guilhaume et al., 2019). Furthermore, mesoporous silica nanoparticles with a core–cone structure were engineered by Li et al., (2019). With proper pore size and PEI functionalization, the particles were utilized to deliver hyaluronan synthase type 2 directly into rat TMJ synoviocytes. Consequently, the endogenous HA production was boosted, with synovial inflammation being inhibited for 3 weeks.

**Novel Delivery Systems for Regenerative Agents**

For the severe types of TMD, such as internal derangement, disc thinning, disc perforation, and osteochondral damage of condyle, regenerative tissue engineering approaches are in demand. Such systems typically consist of bioactive agents, including scaffold, cells, and/or GFs (Donahue et al., 2019; Aryaei et al., 2016; Acri et al., 2019).

In animal models of TMJ damage, natural collagen (Kobayashi et al., 2015; Wang et al., 2017), synthesized PLGA (Zhu et al., 2011; Dormer et al., 2011), polylactic acid (Ahtiainen et al., 2013), and polycaprolactone (PCL) (Tarafder et al., 2016) were fabricated into scaffolds, whereas Pluronic F-127-based hydrogel supported regenerative cell implantation (Yu et al., 2011; Sun et al., 2018). For cells in the systems, articular chondrocytes, costal chondrocytes, whole bone marrow, bone marrow stem cells (BMSCs), and adipose stem cells (Ahtiainen et al., 2013) were adopted. Soluble agents were added to the cell...
culture to modify the biological and physical properties of cells. For instance, NELL-1 was used in the pre-treatment of BMSCs to enhance their chondrogenic differentiation (Zhu et al., 2011). Meanwhile, costal chondrocytes cultured with chondroitinase ABC showed increased tensile ability (Vapniarsky et al., 2018). In regard to the bioactive molecules delivered, the transforming GF (TGF)-β family (Dormer et al., 2011; Ahtiainen et al., 2013; Tarafder et al., 2016), connective tissue growth factor (CTGF), and bone morphogenetic protein-2 were harnessed to regulate the growth and function of the introduced cells and host tissue.

On the other hand, the scaffold-free approaches for regenerative systems are also attractive because they present no problems compared with their scaffold-based counterparts, whose scaffolds may degrade faster than the formation of new tissue or wreaked by toxic degraded polymers (Donahue et al., 2019; Acri et al., 2019). With the passaged, redifferentiated, and self-assembled costal chondrocytes delivered orthotopically as scaffold-free implant, Vapniarsky et al. successfully regenerated the thinned minipig TMJ disc. The material showed gradual amalgamation with the host tissue within 8 weeks (Vapniarsky et al., 2018).

Furthermore, the advancement of fabrication technology strengthened the development of delivery systems. As an example, three-dimensional printing features custom-designed structural and physical properties. Utilizing the different melting temperatures of PLGA and PCL, Tarafder and colleagues encapsulated CTGF and TGF-β3 in PLGA microspheres, which were then embedded in PCL microfibers. Finally, they established a micro-precise anisotropic scaffold and witnessed the multiphased fibrocartilage recovery of rabbit TMJ disc after 4 weeks (Tarafder et al., 2016).

**Hurdles and Prospects of Intra-TMJ Delivery Systems to Treat TMD**

Attempts to develop intra-TMJ delivery systems in animal models are emerging but still limited to several studies thus far. Nevertheless, various novel designs, which have the potential to be applied to IA TMD treatment, are reported in *in vitro* studies for TMJ and in research on other joint disorders (Dashnyam et al., 2018; Donahue et al., 2019). Importantly, recent studies raised quotable ideas to facilitate the improvement of current intra-TMJ delivery systems. First, the advanced agents for administration, such as ion/drug co-delivery (Seo et al., 2017) and antioxidants, can be incorporated (Dashnyam et al., 2018). Second, novel materials can also be employed. For instance, TMJ disc cells are viable and expressed in the matrix of titanium dioxide (TiO₂) nano thin films (Ronald and Mills, 2016). Given the potential of TiO₂ for layer-by-layer nanoassembly (Kommireddy et al., 2006), TiO₂ materials can be developed into deliverer scaffolds. Third, new sources of cells can be adopted, such as Wharton’s jelly-derived mesenchymal stem cells, dental pulp stem cells, nucleus pulposus cells, and induced pluripotent stem cells. Fourth, the optimization of physical properties and incorporation of biophysical stimuli can improve the delivery efficacy (Dashnyam et al., 2018; Donahue et al., 2019; Acri et al., 2019). Finally, preclinical models of large mammals may well mimic TMD pathogenesis in humans and thus promote the bench-to-bedside transition of novel intra-TMJ therapies (Almarza et al., 2018).

**FUTURE PERSPECTIVES**

Over the past 25 years, agents for treating TMD and relative syndromes have evolved from commonly used small molecules to a dynamic field of macromolecules, natural products, and novel functional materials. The translation of novel therapeutic strategies has been greatly inspired by tissue engineering based on the understanding of pathological mechanism of TMD. This field has achieved considerable progress in the satisfied management of pain and inflammatory syndromes and new attempts in the prevention of TMD development by regenerative medicine. As a result of these efforts, growing evidence indicates that adaptive reconstruction of TMJ can be effectively applied in preclinical and clinical studies, which may finally induce satisfied clinical outcomes. Eventually, therapeutic approaches may enable a more effective and personalized therapy for TMD patients.

**AUTHOR CONTRIBUTIONS**

Conceptualization, MJW and MRW; writing and original draft preparation, MJW, JC, YY, SH, and YW; writing and review and editing, MRW; visualization, JC, YY, and MRW; project administration and funding acquisition, MJW. All authors have read and agreed to the published version of the manuscript.

**FUNDING**

This research was supported by Natural Science Foundation of China [grant numbers: 81970956, 81900806]; Zhejiang Qianjiang Talent Project [grant number: QJ1902024].

**REFERENCES**

Acri, T. M., Shin, K., Seol, D., Laird, N. Z., Song, I., Geary, S. M., et al. (2019). Tissue engineering for the temporomandibular joint. *Adv Healthc Mater.* 8, e1801236. doi:10.1002/adhm.201801236
on muscle nerve fibers in pain-free humans and patients with chronic myofascial temporomandibular disorders. J Headache Pain. 15, 63. doi:10.1186/s12291-017-1045-3

Christidis, N., Omrani, S., Fredriksen, L., Gjelseth, M., Louca, S., Hedenberg-Magnusson, B., et al. (2015). Repeated tender point injections of granisetron alleviate chronic myofascial pain—a randomized, controlled, double-blinded trial. J Headache Pain. 16, 104. doi:10.1186/s10194-015-0588-3

Clemente-Napimoga, J. T., Moreira, J. A., Grillo, R., de Melo, L. F., Fraceto, N. F. S., and Napimoga, M. H. (2012). 15d-PGJ2-loaded in nanocapsules enhance the antinociceptive properties into rat temporomandibular hypernociception. Life Sci. 90, 944–949. doi:10.1016/j.lfs.2012.04.035

Clemente-Napimoga, J. T., Silva, M. A. S. M., Peres, S. N. C., Lopes, A. H. P., Lossio, C. F., Oliveira, M. V., et al. (2019). Dioleolues laeclin ameliorates inflammation in the temporomandibular joint of rats by suppressing intercellular adhesion molecule-1 expression. Biochimie. 158, 34–42. doi:10.1016/j.biochi.2018.12.007

Coura, C. O., Chaves, H. V., do Val, D. R., Vieira, L. V., Silva, F. D., Dos Santos Lopes, F. M. L., et al. (2017). Mechanisms involved in antinociception induced by a polysulfated fraction from seaweed Gracilaria cornea in the temporomandibular joint of rats. Int J Biol Macromol. 97, 76–84. doi:10.1016/j.ijbiomac.2017.01.017

Coura, C. O., Souza, R. B., Rodrigues, J. A., Vanderlei Ede, S., de Araújo, I. W., Rodrigues, A. A., et al. (2015). Mechanisms involved in the anti-inflammatory action of a polysulfated fraction from Gracilaria cornea in rats. J Plankton Res. 10, e019319. doi:10.1371/journal.pone.019319

de Conceição Rivanor, R. L., Chaves, H. V., do Val, D. R., de Freitas, A. R., Lemos, J. C., Rodrigues, J. A. G., et al. (2014). A lectin from the green seaweed Caulerpa cupressoides reduces mechanical hyper-nociception and inflammation in the rat temporomandibular joint during zymosan-induced arthritis. Int Immunopharmac. 21, 34–43. doi:10.1016/j.intimp.2014.04.009

Daif, E. T. (2012). Role of intra-arterial ozone gas injection in the management of internal derangement of the temporomandibular joint. Oral surg., oral med., oral pathol. and oral radiol. 113, e10–e14. doi:10.1016/j.tripleo.2011.08.006

Damasceno, M. B. M. V., de Melo Júnior, J. d. M. A., Santos, S. A. R. M., Lør, L. T. M., Leite, L. H. I., Vieira-Neto, A. E., et al. (2016). Frutin reduces acute and neuropathic nociceptive behaviours in rodent models of orofacial pain. Chem Biol Interact. 256, 9–15. doi:10.1016/j.cbi.2016.06.016

Dashnyam, K., Lee, J. H., Mandakhbayar, N., Jin, G.Z., Lee, H.H., and Kim, H. W. (2018). Intra-arterial biomaterials-assisted delivery to treat temporomandibular joint disorders. J Tissue Eng. 9, 201437141876514–1876514. doi:10.1177/2041731418776514

de Almeida, C., and Amenábar, J. M. (2016). Changes in the salivary oxidative status in individuals with temporomandibular disorders and pain. J oral biol. craniol. 6, S1–S4. doi:10.1002/jjobcr.2016.10.006

De Feo, M., Paladini, A., De A., Carducci, A., Del Pinto, R., Varrassi, G., et al. (2020). Anti-inflammatory and anti-nociceptive effects of cocoa: a review on future perspectives in treatment of pain. Pain Ther. 9, 231–240. doi:10.1007/s40122-020-00165-5

Dehghan, M. (2015). Comparative effectiveness of B and e vitamins with diflucenac in reducing pain due to osteoarthritis of the knee. Med Arh. 69, 103–106. doi:10.5455/medarh.2015.69.103-106

de Souza, R. F., Lovato da Silva, C. H., Nasser, M., Fedorowicz, Z., and Al-Muharraqui, M. A. (2012). Interventions for the management of temporomandibular joint osteoarthritis. Cochrane database Syst. Rev. 2012, CD007261. doi:10.1002/14651858.CD007261.pub2

Dimitroulis, G. (2013). A new surgical classification for temporomandibular joint disorders. Int J Oral Maxillofac Surg. 22, 218–222. doi:10.1016/j.ijoms.2012.11.004

do Val, D. R., Bezerra, M. M., Silva, A. A. R., Pereira, K. M. A., Rios, L. C., Lemos, J. C., et al. (2014). Teprosia toxicaria Pers. reduces temporomandibular joint inflammatory hypernociception: the involvement of the HO-1 pathway. Eur J Pain. 18, 1280–1289. doi:10.1016/j.ejpain.2014.08.088

Donahue, R. P., Hu, J. C., and Athanasiou, K. A. (2019). Remaining hurdles for tissue-engineering the temporomandibular joint disc. Trends Mol Med. 25, 241–256. doi:10.1016/j.tmm.2018.12.007

Dormer, N. H., Busaidy, K., Berkland, C. J., and Detamore, M. S. (2011). Osteochondral interface regeneration of rabbit mandibular condyle with
bioactive signal gradients. J Oral Maxillofac Surg. 69, e50–e57. doi:10.1016/j.
joms.2010.12.049

Dos Santos, A. O., do Val, D. R., da Silveira, F. D., Gomes, F. I. F., Freitas, H. C., de Assis, E. L., et al. (2018). Antiinflammatory, anti-inflammatory and toxicological evaluation of semi-synthetic molecules obtained from a benzyl-isothiocyanate isolated from Moringa oleifera Lam. in a temporomandibular joint inflammatory hypernociception model in rats. Biomed Pharmacother. 98, 609–618. doi:10.1016/j. bioph.2017.12.102

Evans, C. H., Kraus, V. B., and Setton, L. A. (2014). Progress in intra-articular therapy. Nat Rev Rheumatol. 10, 11–22. doi:10.1038/nrrheum.2013.159

Fernández-Ferro, M., Fernández-Sanromán, J., Blanco-Carrion, A., Costas-López, A., López-Betancourt, A., Arenaz-Bua, J., et al. (2017). Comparison of intra-articular injection of plasma rich in growth factors versus hyaluronic acid following arthroscopy in the treatment of temporomandibular dysfunction: a randomised prospective study. J Craniomaxillofacial Surg. 45, 449–454. doi:10.1016/j.jcsm.2017.01.010

Finnerup, N. B., Sindrup, S. H., and Jensen, T. S. (2010). The evidence for pharmacological treatment of neuropathic pain. Pain. 150, 573–581. doi:10.1016/j.pain.2010.06.019

Freitas, R. S., do Val, D. R., Fernandes, M. E., Gomes, F. I., de Lacerda, J. T., SantiGadelha, T., et al. (2016). Lectin from Abelmoschus esculentus reduces zymosan-induced temporomandibular joint inflammatory hypernociception in rats via heme oxygenase-1 pathway integrity and tnf-a and il-1β suppression. Int Immunopharmacol. 38, 313–323. doi:10.1016/j.intimp.2016.06.012

Giaccoppo, S., Galuppo, M., Grassi, G., Bramanti, P., and Mazzon, E., (2019). A new formulation of cannabidiol in cream shows therapeutic effects in the treatment of temporomandibular joint in osteoarthritis. J Dent Res. 63, 289–292. doi:10.5555/1334963

Light, K. C., Bragdon, E. E., Greenw, K. M., Brownley, K. A., Girdler, S. S., and Maixner, W. (2009). Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder. J Pain. 10, 542–552. doi:10.1016/j.jpain.2008.12.006

Luo, P., Peng, S., Yan, Y., Ji, P., and Xu, J. (2020). IL-37 inhibits M1-like macrophage activation to ameliorate temporomandibular joint inflammation through the NLRP3 pathway. Rheumatology. 59, 3070–3080. doi:10.1136/rheumatology-kea192

Ma, Y., Liu, S., Shu, H., Crawford, J., Xing, Y., and Tao, F. (2020). Resveratrol alleviates temporomandibular joint inflammatory pain by recovering disturbed gut microbiota. Brain Behav Immun. 87, 455–464. doi:10.1016/j.bbi.2020.01.016

Maigaña-Villa, M., Rocha-González, H., Fernández del Valle-Laisequilla, C., Granados-Soto, V., Rodríguez-Silverio, J., Flores-Murrieta, F., et al. (2013). B-vitamin mixture improves the analgesic effect of diclofenac in patients with osteoarthritis: a double blind study. J Clin Med. 15, 447–452. doi:10.3390/jcm3060421

Magaña-Villa, M., Rocha-González, H., Fernández del Valle-Laisequilla, C., Granados-Soto, V., Rodríguez-Silverio, J., Flores-Murrieta, F., et al. (2013). B-vitamin mixture improves the analgesic effect of diclofenac in patients with osteoarthritis: a double blind study. J Clin Med. 15, 447–452. doi:10.3390/jcm3060421

Martinez, R. M., Zarpelon, A. C., Cardoso, R. D. R., Vicentini, F. T. M. C., Georgetti, S. R., Baracat, M. M., et al. (2013). Tephrosia sinapouethyl acetate extract inhibits inflammatory pain in mice: opioid receptor dependent inhibition of TNFaα and Il-1β production. Pharmaceutic Bioll. 51, 1262–1271. doi:10.1388/38002013.736099

Melo, L. T., Dualibe, M. A. B. P., Pessoa, L. M., do Costa, F. N., Vieira-Neto, A. E., et al. (2008). Pharmacologic management of temporomandibular disorders. Oral Maxillofac Surg Clin North Am. 20, 197–210. doi:10.1016/j.coms.2007.12.005

Nitecka-Buchta, A., Walczynska-Dragon, K., Kempa, W. M., and Baron, S. (2019a). NLC for temporomandibular joint administration. J Dent Res. 63, 289–292. doi:10.5555/1334963

Nitecka-Buchta, A., Walczynska-Dragon, K., Kempa, W. M., and Baron, S. (2019a). NLC for temporomandibular joint administration. J Dent Res. 63, 289–292. doi:10.5555/1334963

Olczyk, P., Batoryna, O., et al. (2019b). Myorelaxant effect of transdermal bisabolol reduces nociception and trigeminal central sensitisation in acute orofacial neuropathic pain induced by infraorbital nerve injury. Life Sci. 122, 122–128. doi:10.1016/j.lfs.2019.04.032

Melo Júnior, J. d. M. d. A. d., Damasceno, M. d. B. M. V., Santos, S. A. A. R., Barbosa, T. M., Araújo, J. R. C., Vieira-Neto, A. E., et al. (2017). Acute and neuropathic orofacial antinociceptive effect of eucalyptol. Inflammopharmacol. 25, 247–254. doi:10.1007/s10787-017-0324-5

Mountziaris, P. M., Singh, D. C., Mikos, A. G., and Kramer, P. R. (2010). Intra-articular microparticles for drug delivery to the TMJ. J Dent Res. 89, 1039–1044. doi:10.1177/1540829X10367526

Mountziaris, P. M., Tsouanas, N. S., Singh, D. C., Kramer, P. R., Fask, F. K., and Mikos, A. G. (2012). Intra-articular controlled release of anti-inflammatory siRNA with biodegradable polymer microparticles ameliorates temporomandibular joint inflammation. Acta Biomater. 8, 3552–3560. doi:10.1016/j.actbio.2012.06.031

Nitecka-Buchta, A., Walczynska-Dragon, K., Kempa, W. M., and Baron, S. (2019a). Platelet-rich plasma intramuscular injections - antinociceptive therapy in myofascial pain within masseter muscles in temporomandibular disorders patients: a pilot study. Front Neurol. 10, 250. doi:10.3389/fneur.2019.00250

Nitecka-Buchta, A., Nowak-Wachol, A., Wachol, K., Walczynska-Dragon, K., Olczyk, P., Batoryna, O., et al. (2019b). Myorelaxant effect of transdermal cannabidiol application in patients with TMD: a randomized, double-blind trial. J Clin Med. 8, 1886. doi:10.3390/jcm8111886

Nourshargh, S., and Alon, R. (2014). Leukocyte migration into inflamed tissues. Immunity. 41, 694–707. doi:10.1016/j.immuni.2014.10.008

LeResche, L., Mandl, L., Sherman, J. J., Gandara, B., and Dworkin, S. F. (2003). Changes in temporomandibular pain and other symptoms across the menstrual cycle. Pain. 106, 253–261. doi:10.1016/j.pain.2003.06.001

Li, J. W.-H., and Vederas, J. C. (2009). Drug discovery and natural product: end of an era or an endless frontier? Science. 325, 161–165. doi:10.1126/science.1168243

Li, H., Guo, H., Lei, C., Liu, L., Xu, L., Feng, Y., et al. (2019). Nanotherapy in joints: increasing endogenous hyaluronan production by delivering hyaluronan synthase 2. Adv Mater. 31, e1904535. doi:10.1002/adma.201970331

Evans, C. H., Kraus, V. B., and Setton, L. A. (2014). Progress in intra-articular therapy. Nat Rev Rheumatol. 10, 11–22. doi:10.1038/nrrheum.2013.159
Oliveira-Fusaro, M. C. G., Clemente-Napimoga, J. T., Teixeira, J. M., Torres-Chávez, K. E., Parada, C. A., and Tambelli, C. H. (2012). 5-HT induces temporomandibular joint nociception in rats through the local release of inflammatory mediators and activation of local β adrenoceptors. *Pharmacol Biochem Behav.* 102, 458–464. doi:10.1016/j.pbb.2012.06.005

Osiewicz, M. A., Lobbezoo, F., Loster, B. W., Loster, J. E., and Manfredini, D. (2018). Frequency of temporomandibular disorders diagnoses based on RDC/TMD in a Polish patient population. *Cranio: The Journal of Craniofacial Pain & Craniofacial disorders.* 36, 304–310. doi:10.1080/07388551.2017.1361052

Ouanonou, A., Goldberg, M., and Haas, D.A. (2017). Pharmacotherapy in temporomandibular disorders: a review. *Journal (Canadian Dental Association).* 83, 1-7.

Paramasivan, K., and Mutturi, S., (2017). Progress in terpene synthesis strategies through engineering of Sarcococca cerasifera. *Citr Rev Biotechnol.* 37, 974–989. doi:10.1007/s10527-017-99267-9

Peck, C. C., Goulet, J.-P., Lobbezoo, F., Schiffman, E. L., Alstergren, P., Anderson, G. C., et al. (2014). Expanding the taxonomy of the diagnostic criteria for temporomandibular disorders. *J Oral Rehabil.* 41, 2–23. doi:10.1111/joor.12132

Pongratz, G., and Straub, R. H. (2013). Role of peripheral nerve inflammation in temporomandibular joint nociception in rats through the local release of 5-HT. *Pain Physician.* 16, 2977. doi:10.3892/etm.2018.6551

Robinson, J. L., Johnson, P. M., Kister, K., Yin, M. T., Chen, J., and Wadhwa, S. (2018). Estrogen promotes mandibular condylar cartilage development in the rabbit temporomandibular joint using a collagen template. *Materials.* 10, 924. doi:10.3390/ma10080924

Webb, D., and Naidoo, P. (2018). Viscosupplementation for knee osteoarthritis: a focus on Hylan G-F 20. *Orr.* 10, 73–81. doi:10.2174/11746469

Wu, D., Huang, Y., Gu, Y., and Fan, W., (2011). Platelet-rich plasma inhibits RANKL-induced osteoclast differentiation through activation of Wnt pathway during bone remodeling. *J Int Med.* 41, 729–738.

Wu, R. M., Chen, W. P., Chiu, L. H., Tsai, Y. H., Fang, C. L., Yang, C. B., et al. (2010). Histological and immunohistochemical analyses of repair of the disc in the rabbit temporomandibular joint using a collagen template. *Materials.* 10, 924. doi:10.3390/ma10080924

Wu et al. Pharmaceutical Agents for TMD Treatment

Tamaddonfard, E., Tamaddonfard, S., and Cheraghian, S. (2018). Effects of intracerebroventricular injection of vitamin B12 on formalin-induced muscle pain in rats: role of cyclooxygenase pathway and opioid receptors. * Vet Res Forum.* 9, 329–335. doi:10.4146/vetresforum.2018.33194

Töth, C. C., Jedrzejewski, N. M., Ellis, C. L., and Frey, W. H. (2010). 2nd, Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. *Pain Med.* 6. 16. doi:10.1111/j.1744-8069.2010.00611.x

Vapniarsky, N., Huwe, L. W., Arzi, B., Houghton, M. K., Wong, M. E., Wilson, J. W., et al. (2018). Tissue engineering toward temporomandibular joint disc regeneration. *Sci Transl Med.* 10. doi:10.1126/scitranamed.aq8102

Villa, G., Ceruti, S., Zanardelli, M., Magni, G., Jasmin, L., Ohara, P.T., et al. (2010). Temporomandibular joint inflammation activates glial and immune cells in both the trigeminal ganglia and in the spinal trigeminal nucleus. *Pain Med.* 8. 6. doi:10.1181/1744-8069.2010.00611.x

Wang, D., Weng, Y., Guo, S., Zhang, Y., Zhou, T., Zhang, M., et al. (2018). Platelet-rich plasma inhibits RANKL-induced osteoclast differentiation through activation of Wnt pathway during bone remodeling. *J Int Med.* 41, 729–738.

Xu, D. H., Dallen, B. D., Yang, M., and Fang, Y. (2020). The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. *Curr. Pharm. Biotechnol.* 21, 390–402. doi:10.2174/1389201020666191202111534

Yang, J. W., Huang, C. Y., Wu, S. L., Ko, S. Y., and Tsai, C. C., (2017). Clinical efficacy of a centric relation occlusal splint and intra-articular liquid phase concentrated growth factor injection for the treatment of temporomandibular disorders. *Medicine.* 96. 6302. doi:10.1097/md.00000000006302

Yip, K., and Oettinger, J., (2020). Why are we still using opioids for TMD? *Int Clin Pract.* 75. doi:10.1111/icp.13146

Yu, X. H., Cao, C. Q., Martino, G., Puma, C., Morinville, A., St-Onge, S., et al. (2011). Distraction for the repair of the goat condylar cartilage stromal cells and chondrocytes. *Exp Ther Med.* 9, 154. doi:10.3892/etm.2010.515

Yu, H., Yang, X., Cheng, J., Wang, X., and Shen, S. G., (2011). Ozone therapy in dental and oral medicine. *Med Gas Res.* 16, 334–340. doi:10.2147/ogr.s13416
Zotti, F., Albanese, M., Rodella, L.F., and Nocini, P. F. (2019). Platelet-rich plasma in treatment of temporomandibular joint dysfunctions: narrative review. *Int J Mol Sci.* 20, 277. doi:10.3390/ijms20020277

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.